MedTrace Logo

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT00252499 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral insulin sensitivity, hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, beta-cell function and body fat distribution.

Conditions

Interventions

DRUG

rosiglitazone

PPAR-gamma agonist, insulin sensitizer

DRUG

fenofibrate

PPAR-alpha agonist, reduces triglycerides

DRUG

placebo for rosiglitazone

placebo tablets that are matched to look like rosiglitazone

DRUG

placebo for fenofibrate

placebo matched to look like fenofibrate tablets

Sponsors & Collaborators

Principal Investigators

  • Kristina Marie Utzschneider, MD · VA Puget Sound Health Care System, Seattle

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252499 on ClinicalTrials.gov